PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis

Inclusion Criteria:

1. Written informed consent (and assent when applicable) obtained from participant orparticipant's legal representative
2. Enrolled in the CFF Patient Registry (CFF PR)
3. Be willing and able to adhere to study procedures in the context of clinical care, andother protocol requirements
4. Male or female participant ≥ 6 years of age at enrollment
5. Diagnosis of CF consistent with the 2017 CFF Guidelines
6. NTM positive for a species or sub-species in the 2 years prior to enrollment that hasnever been treated.
7. Willing to discontinue chronic azithromycin use for the duration of the study

Exclusion Criteria:

1. Prior or ongoing antibiotic treatment of the same NTM species or sub-species for whichthe patient is being considered for this study
2. History of solid organ or hematological transplantation
3. Has any other condition that, in the opinion of the Site Investigator/designee, wouldpreclude informed consent or assent, make study participation unsafe, complicateinterpretation of study outcome data, or otherwise interfere with achieving the studyobjectives